19 June 2013
Keywords: ph, ii, data, texas, novastan, acute, mi
Article | 07 April 1997
Texas Biotechnology has reported promising Phase II data from two trialswith Novastan (argatroban for injection), as an adjunctive therapy to
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 April 1997
© 2013 thepharmaletter.com